BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17133426)

  • 1. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
    Tong Y; Qian J; Li Y; Meng H; Jin J
    Am J Hematol; 2007 May; 82(5):403-4. PubMed ID: 17133426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
    Hasegawa Y; Kawahara F; Nagai H; Hirose T; Imai Y; Ishiguro T; Chou T
    Rinsho Ketsueki; 2009 Jun; 50(6):488-94. PubMed ID: 19571509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
    Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
    J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aggravated post-herpetic neuralgia due to bortezomib].
    Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
    Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
    Chanan-Khan A; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Neuwirth R; Anderson KC; Richardson PG
    J Clin Oncol; 2008 Oct; 26(29):4784-90. PubMed ID: 18711175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PAD regimen for relapsed or refractory patients with multiple myeloma].
    Zhang YQ; Liang R; Bai QX; Zhang T; Yang L; Wang YW; Wang WQ; Gu HT; Shu MM; Zhu HF; Bai YN; Chen XQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):260-3. PubMed ID: 19731828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
    Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
    Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib and bilateral herpes zoster.
    di Meo N; Bergamo S; Dondas A; Trevisan G
    Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
    Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
    Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
    Oakervee HE; Popat R; Curry N; Smith P; Morris C; Drake M; Agrawal S; Stec J; Schenkein D; Esseltine DL; Cavenagh JD
    Br J Haematol; 2005 Jun; 129(6):755-62. PubMed ID: 15953001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected cardiotoxicity in haematological bortezomib treated patients.
    Enrico O; Gabriele B; Nadia C; Sara G; Daniele V; Giulia C; Antonio S; Mario P
    Br J Haematol; 2007 Aug; 138(3):396-7. PubMed ID: 17561972
    [No Abstract]   [Full Text] [Related]  

  • 19. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
    Vickrey E; Allen S; Mehta J; Singhal S
    Cancer; 2009 Jan; 115(1):229-32. PubMed ID: 19090004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
    Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
    Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.